We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SomaLogic Logo

SomaLogic

SomaLogic is fostering the discovery of effective and safer treatments for patients while empowering more accurate diagnosis, prevention and treatment of disease through the next generation of proteomics.

Latest SomaLogic Content

soma logic technology networks webinar 6th June 2023
Webinar

Using Proteomics To Advance Understanding of Alzheimer’s Disease

In this webinar, we’ll explore how integrating proteomics with systems biology sheds light on the complexities of AD pathology.
11K graphic, representing 11,000 human protein measurements using the SomaScan Assay
Product
Advertisement

SomaScan® 11K Assay Services: Unparallelled Protein Content for High-Plex Protein Profiling and Biomarker Discovery

Introducing the SomaScan® 11K Assay – Pioneering proteomics. SomaLogic's high-plex, high throughput assay covers half the human proteome, empowering researchers to identify unique pathway and protein signatures. Explore the power of more.
Somalogic Webinar
Webinar

Identifying Biomarkers for IBD Diagnosis and Management

On-Demand
Driving biomarker discovery is key as proteomics emerges as the next frontier in precision medicine.
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
This webinar will explore how reliable, non-invasive proteomic biomarkers are pivotal for personalized treatment and increasing our knowledge of biological pathways involved in disease. Our expert speaker will also present an assay platform that can measure 11,000 biologically relevant proteins in the search for biomarkers.
A doctor holding a clipboard with a patient.
Product News

OncoHost To Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.
Somalogic
Webinar

Using Plasma Proteomics To Understand Alzheimer’s and Other Brain Diseases

On-Demand
Dr. Walker will discuss how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.
High-Throughput Protein Profiling: Discover New Disease Biomarkers content piece image
Infographic

High-Throughput Protein Profiling: Discover New Disease Biomarkers

While most protein assays excel in one or two areas, the SomaScan Assay is the first and only platform that can measure 7,000 proteins from a 55-µL sample – covering more biological pathways than any other proteomic assay.
Discovery of Blood-Based Biomarkers in Neurodegenerative Diseases content piece image
Whitepaper

Discovery of Blood-Based Biomarkers in Neurodegenerative Diseases

The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.
Discover Novel Biomarkers for Drug Discovery and Clinical Diagnostics content piece image
App Note / Case Study

Discover Novel Biomarkers for Drug Discovery and Clinical Diagnostics

Developed for performance in human serum and plasma, the SomaScan Assay v4.1 can measure approximately 7,000 unique human protein analytes in small volumes of biological samples.
The OncoHost logo
Product News

OncoHost To Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at SITC 2022

OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitor in non-small cell lung cancer patients.
Using the SomaSignal® Tests for Pre-Analytical Variation Assessments With Joe Gogain content piece image
Video

Using the SomaSignal® Tests for Pre-Analytical Variation Assessments With Joe Gogain

In this Teach Me in 10 episode, Joe Gogain, director of clinical research and development at SomaLogic, will be discussing SomaSignal™ Tests.
Advertisement